Oregon Attorney General Dan Rayfield filed a $900 million lawsuit against the nation’s largest insulin manufacturers, ...

The lawsuit alleges three manufacturers coordinated with three pharmacy benefit managers in a scheme to inflate insulin ...

Explore India's urgent need to bridge the healthcare gap for children with Type 1 Diabetes (T1D) by ensuring universal access ...

Insulin is often cited as a prime example of soaring drug costs after years of price hike by drug manufacturers.

The global diabetes injection pens market is projected to grow at a CAGR of approximately 7% through 2028. Market expansion ...

For most healthy women, optimal fasting insulin levels should be less than 25 mIU/L (milli-international units per liter), ...

The gray-market drugs flooding Silicon Valley reveal a community that believes it can move faster than the F.D.A.

For many of these uses, the scientific backing is far weaker than that for GLP-1 drugs. Yet many users extrapolate from the ...

French pharma Sanofi (Euronext: SAN) has won US priority review for Tzield (teplizumab-mzwv), aiming to extend use to ...

CivicaScript®, LLC, a nonprofit company dedicated to bringing low-cost generic medicines and biosimilars to U.S. patients, today announced the availability of two new products: insulin glargine-yfgn ...

Peptides are everywhere; they’re unavoidable. Insulin is a peptide. So are GLP-1s—the Ozempics and Mounjaros of the world.

WANNABE slimmers were today urged not to suddenly restart fat jabs at the same dose after pressing pause over Christmas.